Ectopic expression of C/EBPα and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia

Haematologica

Volumn 94, Issue 8, 2009, Pages 1075-1084

  Geest, Christian R ^a   Buitenhuis, Miranda ^a   Vellenga, Edo ^b   Coffer, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

C ebp ; Hematopoiesis; ID1; Myelodysplastic syndrome; Myeloid

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD34 ANTIGEN; INHIBITOR OF DIFFERENTIATION 1; PROTEIN KINASE B; RETROVIRUS VECTOR; STAT5 PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL ISOLATION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; COLONY FORMING UNIT M; CONTROLLED STUDY; EX VIVO STUDY; GENETIC TRANSDUCTION; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL EXPANSION;

ADULT; AGED; ANTIGENS, CD34; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW CELLS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; GENE EXPRESSION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPHILS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; STAT5 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 68049143163     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.000471     Document Type: Article

References (62)

1. Lowenthal RM, Marsden KA. Myelodysplastic syndromes. Int J Hematol 1997;65:319-38.
2. Fenaux P. Myelodysplastic syndromes: from pathogenesis and prognosis to treatment. Semin Hematol 2004;41:6-12.
3. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000;14:2-8.
4. Kouides P, Bennett J. Understanding the myelodysplastic syndromes. Oncologist 1997;2:389-401.
5. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649-60.
6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
7. Vardiman JW. The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MD. Clin Adv Hematol Oncol 2003;1:18-21.
8. Maschek H, Gutzmer R, Choritz H , Georgii A. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients. Eur J Haematol 1994;53:280-7.
9. Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002;16:2366-78.
10. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q-anomaly. Cancer Genet Cytogenet 1985;17:189-255.
11. Asimakopoulos FA, White NJ, Nacheva E, Green AR. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 1994;84:3086-94.
12. Le Beau MM, Espinosa R, Davis EM, Eisenbart JD, Larson RA , Green ED. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 1996;88:1930-5.
13. Preudhomme C, Vanrumbeke M, Lai JL, Lepelley P, Wattel E , Fenaux P. Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy. Leukemia 1994;8:2241-2.
14. Preudhomme C, Vachee A, Lepelley P, Vanrumbeke M, Zandecki M, Quesnel B, et al. Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. Br J Haematol 1994;87:61-7.
15. Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21:1988-95.
16. Preudhomme C, Vachee A, Quesnel B, Wattel E, Cosson A, Fenaux P. Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia 1993;7:1071.
17. Fuchs O, Provaznikova D, Kocova M, Kostecka A, Cvekova P, Neuwirtova R, et al. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Mol Dis 2008;40:401-5.
18. Nilsson L, Edén P, Olsson E, Månsson R, Astrand- Grundström I, Strömbeck B, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 2007;110:3005-14.
19. Zhang Y, Zhang M, Yang L , Xiao Z. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leuk Res 2007;31:109-11.
20. Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997;11:1442-6.
21. Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 1998;12:887-92.
22. Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E. Mutations in the RAS proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 1994;8:638-41.
23. Harada H, Harada Y, Niimi H, Kyo T, Kimura A , Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004;103:2316-24.
24. + cells. Blood 2003;101:134-42.
25. Buitenhuis M, van Deutekom HWM, Verhagen LP, Castor A, Jacobsen SEW, Lammers JJ, et al. Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors ID1 and ID2. Blood 2005;105:4272-81.
26. Buitenhuis M, Verhagen LP, van Deutekom HWM, Castor A, Verploegen S, Koenderman L, et al. Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood 2008;111:112-21.
27. Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006;108:4170-7.
28. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene 2007;26:6724-37.
29. Fuhler GM, Drayer AL, Olthof SGM, Schuringa JJ, Coffer PJ, Vellenga E. Reduced activation of protein kinase B, RAC, and F-actin polymerization contributes to an impairment of stromal cell derived factor-1 induced migration of CD34+ cells from patients with myelodysplasia. Blood 2008;111:359-68.
30. Fuhler GM, Drayer AL, Vellenga E. Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia. Blood 2003;101:1172-80.
31. Schuringa JJ, Chung KY, Morrone G, Moore MAS. Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med 2004;200:623-35.
32. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPα), in acute myeloid leukemia. Nat Genet 2001;27:263-70.
33. Gombart AF, Hofmann W, Kawano S, Takeuchi S, Krug U, Kwok SH, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002;99:1332-40.
34. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia 2005;19:329-34.
35. Raza A, Alvi S, Borok RZ, Span L, Parcharidou A, Alston D, et al. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship. Leuk Lymphoma 1997;27:111-8.
36. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000;12:1-13.
37. Katsoulidis E, Li Y, Yoon P, Sassano A, Altman J, Kannan-Thulasiraman P, et al. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 2005;65:9029-37.
38. Follo MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, Chiarini F, et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007;67:4287-94.
39. Bunting KD, Bradley HL, Hawley TS, Moriggl R, Sorrentino BP, Ihle JN. Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood 2002; 99:479-87.
40. Snow JW, Abraham N, Ma MC, Abbey NW, Herndier B, Goldsmith MA. STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells. Blood 2002;99:95-101.
41. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, et al. STAT5a and STAT5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998;93:841-50.
42. Ilaria RLJ, Hawley RG, Van Etten RA. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 1999;93:4154-66.
43. Kieslinger M, Woldman I, Moriggl R, Hofmann J, Marine JC, Ihle JN, et al. Antiapoptotic activity of STAT5 required during terminal stages of myeloid differentiation. Genes Dev 2000;14:232-44.
44. Perk J, Iavarone A , Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 2005;5: 603-14.
45. Cooper CL, Newburger PE. Differential expression of Id genes in multipotent myeloid progenitor cells: Id-1 is induced by early- and late-acting cytokines while Id-2 is selectively induced by cytokines that drive terminal granulocytic differentiation. J Cell Biochem 1998;71: 277-85.
46. Han S, Gou C, Hong L, Liu J, ZheyiHan, Liu C, et al. Expression and significances of Id1 helix-loop-helix protein overexpression in gastric cancer. Cancer Lett 2004;216: 63-71.
47. Wang Q, Tsao SW, Fu S, Xue W, Meng X, Feng H, et al. Overexpression of Id-1 in gastric adenocarcinoma: implication for a novel diagnostic marker. Anticancer Res 2004;24:881-6.
48. Ishiguro A, Spirin K, Shiohara M, Tobler A, Norton JD, Rigolet M, et al. Expression of Id2 and Id3 mRNA in human lymphocytes. Leuk Res 1995;19:989-96.
49. Suh HC, Leeanansaksiri W, Ji M, Klarmann KD, Renn K, Gooya J et al. Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene 2008; Jun 9 [Epub ahead of print]
50. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000;404:193-7.
51. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998;18:4301-14.
52. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 1997;94:569-74.
53. Wang X, Scott E, Sawyers CL, Friedman AD. C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999;94:560-71.
54. Zhang P, Nelson E, Radomska HS, Iwasaki-Arai J, Akashi K, Friedman AD, et al. Induction of granulocytic differentiation by 2 pathways. Blood 2002;99:4406-12.
55. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, et al. AML1/ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001;7:444-51.
56. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002;30:48-58.
57. Helbling D, Mueller BU, Timchenko NA, Hagemeijer A, Jotterand M, Meyer-Monard S, et al. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of calreticulin. Proc Natl Acad Sci USA 2004;101:13312-7.
58. Silverman LR. DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol 2004;17:585-94.
59. Wouters BJ, Jordà MA, Keeshan K, Louwers I, Erpelinck-Verschueren CAJ, Tielemans D, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007;110:3706-14.
60. Zhang P, Iwama A, Datta MW, Darlington GJ, Link DC , Tenen DG. Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis. J Exp Med 1998;188:1173-84.
61. Smith LT, Hohaus S, Gonzalez DA, Dziennis SE , Tenen DG. PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 1996;88:1234-47.
62. Sultana TA, Harada H, Ito K, Tanaka H, Kyo T, Kimura A. Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia. Br J Haematol 2003;121:63-75.